Benzinga · Aug 14, 2026
RBC Capital Maintains Outperform on Ventas, Raises Price Target to $99
RBC Capital analyst Michael Carroll maintains Ventas (NYSE:VTR) with a Outperform and raises the price target from $98 to $99.
NYSE · VTR
Ventas, Inc.
Real Estate · REIT - Healthcare Facilities
$91.52
Up+$1.23 (+1.36%)
Updated Aug 16, 2026, 10:03 AM
SID Score
5.6/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 34.19B
- P/E ratio
- 611.21
- Dividend yield
- 2.07%
- 52-week range
- $73.82 – $101.60
- Volume
- 3M
- Avg. volume
- 2.95M
Price performance
VTR price history
1M range · 20 trading sessions · Daily adjusted prices
VTR closed at $91.52 after 20 trading sessions, down 4.91% for the selected period.
- Last close
- $91.52
- Period change
- -4.91%
- Period low
- $86.96
- Period high
- $100.53
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | $90.19 | $91.615 | $90.155 | $91.52 | 3M |
| Aug 13, 2026 | $89.49 | $90.57 | $89.35 | $90.29 | 2.31M |
| Aug 12, 2026 | $86.94 | $89.14 | $86.94 | $89.01 | 2.56M |
| Aug 11, 2026 | $90.82 | $90.89 | $86.92 | $86.96 | 4.89M |
| Aug 10, 2026 | $92.00 | $92.97 | $91.54 | $91.95 | 2.89M |
| Aug 7, 2026 | $91.80 | $93.395 | $91.74 | $93.36 | 2.28M |
| Aug 6, 2026 | $93.27 | $93.27 | $91.705 | $92.26 | 2.2M |
| Aug 5, 2026 | $90.76 | $92.97 | $90.18 | $92.53 | 3.46M |
| Aug 4, 2026 | $89.90 | $91.26 | $88.45 | $90.85 | 3.28M |
| Aug 3, 2026 | $93.08 | $94.0674 | $90.815 | $90.85 | 4.41M |
| Jul 31, 2026 | $92.04 | $94.12 | $90.27 | $93.51 | 4.3M |
| Jul 30, 2026 | $96.80 | $97.605 | $90.86 | $91.92 | 6.34M |
| Jul 29, 2026 | $98.19 | $98.87 | $96.92 | $97.72 | 4.5M |
| Jul 28, 2026 | $101.46 | $101.60 | $98.09 | $98.14 | 4.79M |
| Jul 27, 2026 | $100.32 | $100.98 | $99.71 | $100.11 | 3.89M |
| Jul 24, 2026 | $98.47 | $100.84 | $98.215 | $100.53 | 2.87M |
| Jul 23, 2026 | $97.43 | $98.84 | $96.64 | $97.92 | 2.81M |
| Jul 22, 2026 | $97.87 | $97.945 | $96.75 | $97.18 | 2.53M |
| Jul 21, 2026 | $96.05 | $97.64 | $95.84 | $97.62 | 2.4M |
| Jul 20, 2026 | $96.02 | $96.62 | $95.475 | $96.25 | 2.58M |
Latest VTR news
The latest Smart Investors Daily articles mentioning VTR.
Stock researchCompany · Overview
VTR research
Overview
Company profile and research snapshot.
Company profile
Ventas owns a diversified healthcare portfolio of almost 1,400 in-place properties spread across the senior housing, medical office, hospital, life science, and skilled nursing/post-acute care. The portfolio includes almost 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to the United States. The firm also owns mortgages and other loans, contributing about 1% of net operating income.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $80.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2026 | RBC Capital | Outperform | — |
| Aug 11, 2026 | BMO Capital | Outperform | — |
| Aug 4, 2026 | Citigroup | Buy | — |
| Jul 31, 2026 | Cantor Fitzgerald | Overweight | — |
| Jul 22, 2026 | Mizuho | Outperform | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 12, 2026
National Health Investors: Buy The Earnings Dip And Lock In A 5.3% Yield
National Health Investors, Inc. near 52-week lows: 5.3% yield, discounted P/FFO, SHOP growth catalyst, and rising dividend outlook. Click for this NHI update.
Yahoo · Aug 11, 2026
Top Research Reports for Meta, Texas Instruments & CrowdStrike
Meta's AI expansion across apps faces margin pressure and uncertain monetization, while WhatsApp and AI glasses add new avenues.
Benzinga · Aug 11, 2026
BMO Capital Maintains Outperform on Ventas, Raises Price Target to $107
BMO Capital analyst John Kim maintains Ventas (NYSE:VTR) with a Outperform and raises the price target from $105 to $107.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
